Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN has launched its QIAwave product line, introducing three nucleic acid extraction kits that significantly reduce environmental waste. The new kits use up to 63% less plastic and 42% less cardboard compared to standard products. This initiative marks a significant move towards sustainability, aiming to decrease plastic packaging waste by an additional 9% in 2022 after a 9.6% reduction in 2021. The company also aims for net-zero carbon emissions by 2050, receiving a top “Prime” rating from ISS ESG for its efforts.
QIAGEN N.V. (NYSE: QGEN) has announced significant enhancements to its QIAstat-Dx syndromic testing solution, aiming to improve testing capacities for pathogens. New tests include a Gastrointestinal panel for U.S. regulatory approval, designed to detect 22 pathogens, and CE-IVD registration for a Meningitis/Encephalitis panel analyzing 15 pathogens. The new QIAstat-Dx Rise platform, launching in mid-2022, features enhanced efficiency with a Smart Drawer system capable of processing up to 160 tests per day. These advancements respond to increased demand for rapid testing amid ongoing health challenges.
QIAGEN N.V. (NYSE: QGEN) has announced the expansion of its QIAcuity digital PCR platform, now offering non-invasive prenatal testing (NIPT) through collaboration with Atila BioSystems and introducing protein analysis capabilities via a partnership with Actome GmbH. The enhancements reduce sample processing time to 2.5 hours and increase multiplexing capabilities. QIAcuity is also highlighted for its application in detecting rare cancer mutations and testing wastewater for SARS-CoV-2. These advancements aim to establish QIAcuity as a new standard in PCR technology.
QIAGEN N.V. (NYSE: QGEN) announced significant expansions to its QuantiFERON franchise, enhancing its tuberculosis detection capabilities and introducing new applications for latent disease detection. The QuantiFERON SARS-CoV-2 assay, launched in December 2021, has received CE marking to measure T-cell responses to COVID-19. Additionally, the QuantiFERON-TB Gold Plus assay now includes more patient groups as approved by the FDA. The QIAreach QuantiFERON-TB test aims to improve TB detection in resource-limited settings and is now approved for public health procurement in over 100 countries.
Denovo Biopharma and QIAGEN announced a collaboration to develop a blood-based companion diagnostic test for patients with diffuse large B-cell lymphoma (DLBCL). This test aims to identify individuals expressing the Denovo Genomic Marker 1 (DGM1), who may respond to Denovo's investigational drug DB102. The development involves a real-time PCR assay for the QIAGEN Rotor-Gene Q MDx instrument, with plans to seek premarket approval from the FDA. Denovo's DB102 is currently in a Phase III trial for DLBCL and glioblastoma multiforme and has received several FDA designations.
QIAGEN has partnered with Denovo Biopharma to develop a blood-based companion diagnostic test for Diffuse Large B-Cell Lymphoma (DLBCL) patients likely to respond to Denovo's investigational drug DB102. The collaboration seeks FDA premarket approval (PMA) alongside the new drug application (NDA) for DB102. This agreement bolsters QIAGEN's precision medicine initiatives and its oncology testing portfolio. The test will detect Denovo Genomic Marker 1 (DGM1), enhancing treatment personalization for DLBCL patients.
QIAGEN has announced the CE marking of its QuantiFERON® SARS-CoV-2 assay, which measures T-cell responses to SARS-CoV-2, enhancing the assessment of immunity post-COVID-19 vaccination. Unlike traditional serology tests, this assay evaluates both CD4+ and CD8+ T-cell responses, providing deeper insights into immune responses. The technology is designed for ease of use, requiring only whole blood and no lymphocyte purification. T-cell responses offer critical information on the immune system's effectiveness against COVID-19 over time.
QIAGEN has received additional FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay on DiaSorin's LIAISON® XS platform. This expands access to automated TB testing solutions across diverse healthcare settings, from small clinics to large hospitals. The QuantiFERON test, a leading interferon-gamma release assay (IGRA), enhances patient care by replacing outdated tuberculin skin tests. The partnership with DiaSorin enhances the ability to meet the rising demand for TB detection, which affects around one-third of the global population.
QIAGEN N.V. (NYSE: QGEN) confirmed that its PCR tests remain effective in detecting SARS-CoV-2 infections amid the emergence of the B.1.1.529 variant from South Africa. The efficacy was validated through data from GISAID and GenBank. QIAGEN’s tests include the artus SARS-CoV-2 Prep&AMp;Amp UM Kit, QIAstat-Dx systems, and NeuMoDx PCR systems, all confirming reliable results against the new variant. The company will continue biweekly surveillance on its tests' performance to adapt to further viral mutations.
QIAGEN N.V. (NYSE: QGEN) has joined the "Business Ambition for 1.5˚C" campaign, committing to achieve net-zero carbon emissions by 2050. The company aims for a minimum of 40% reduction in Scope 1 and 2 emissions, and 10% in Scope 3 emissions by 2030 from a 2020 baseline. This initiative aligns with the Paris Climate Agreement and positions QIAGEN among over 2,000 global entities in the Race to Zero Campaign. QIAGEN is embedding environmental sustainability into operations, including using renewable energy and reducing packaging plastics.